Overview

Dapagliflozin in the Prevention of Post-Coronary Angioplasty Acute Kidney Injury

Status:
Not yet recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
To compare the incidence of acute kidney injury (AKI) post percutaneous coronary intervention (PCI) in a Dapagliflozin treated group versus a group managed with the standard of care.
Phase:
Early Phase 1
Details
Lead Sponsor:
Albert Einstein Healthcare Network
Treatments:
Dapagliflozin